August 2012
-
Inhaler monitoring company Adherium has announced the appointment of Francis White as VP of Global Business Development. White was most recently Managing Director of Olympus Medical in the UK and Ireland and previously held business… Read more . . .
-
According to Iliad Biotechnologies, the company has received a 3-year, $1 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) for pre-clinical development of its B-Tech intranasal… Read more . . .
-
Virpax Pharmaceuticals said that nasal delivery of its VRP324 dry powder cannabidiol in a rodent model produced high concentrations of CBD in the brain. In September 2021, Virpax announced that it had licensed Nanomerics’s molecular envelope… Read more . . .
-
Australian pharmaceutical company Firebrick Pharma has announced the initiation of a Phase 2 trial of its Nasodine povidone-iodine nasal spray for the reduction of viral shedding in patients with COVID-19. According to Firebrick, a 2001 pilot… Read more . . .
-
The FDA has granted Breakthrough Therapy designation to Zambon’s CMS I-neb colistimethate sodium for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult patients with chronic P. aeruginosa lung infections, the company said. The FDA… Read more . . .
-
Inhalation API manufacturer Inke has announced a €9 million expansion of its manufacturing facility in Castellbisbal, Barcelona, Spain “to reinforce focus on inhalation micronized APIs,” with the aim of tripling its production capacity by 2024.… Read more . . .
-
Researchers from Rensselaer Polytechnic Institute (RPI) and Albany Medical College will use a $500,000 grant from the New York State Biodefense Commercialization Fund for early development of a pentosan polysulfate (PPS) nasal spray for the… Read more . . .
-
TFF Pharmaceuticals announced that a Phase 1 SAD/MAD study of its dry powder niclosamide found that inhalation of the formulation was well tolerated at all doses evaluated and that data from the study suggest moving… Read more . . .
-
SK Bioscience announced that it has partnered with nonprofit research organization IAVI on development of an antiviral nasal spray based on a protein developed by David Baker at the University of Washington. The company noted… Read more . . .
-
Researchers from Northwestern University, the University of Washington, and Washington University at St. Louis have published data demonstrating that select miniproteins neutralized SARS-CoV-2 better than mAbs currently in use for the treatment of COVID-19. The… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.